Enliven Therapeutics shares are trading higher after HC Wainwright & Co. maintained its Buy rating and raised the price target on the stock from $48 to $56.

Benzinga Newsdesk www.benzinga.com Positive 94.8%

Neg 0% Neu 0% Pos 94.8%

Comments

No comments yet. Be the first!